Mineralys Therapeutics (MLYS) Earnings Date & Reports
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
MLYS is expected to report earnings to rise 34.18% to -105 cents per share on August 11
Q2'25
Est.
$-1.06
Q1'25
Beat
by $0.29
Q4'24
Missed
by $0.27
Q3'24
Missed
by $0.42
Q2'24
Missed
by $0.11
The last earnings report on May 12 showed earnings per share of -79 cents, beating the estimate of -108 cents. With 415.80K shares outstanding, the current market capitalization sits at 1.02B.